Summary: NephroGenex is a drug development company focusing on kidney disease. The company is developing Pyridorin™ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease. Pyridorin™ has demonstrated a significant treatment effect in slowing the progression of diabetic nephropathy in two Phase IIa clinical trials, and has been awarded Fast Track status by the FDA.
Total raised: $3.3M

Investors 1

Funding Rounds 1

DateSeriesAmountInvestorsDeal News

Mentions in press and media 2

29.06.2016The biotec...There was a time af­ter the 20...FinancingJohn Carro...endpts.com...
10.07.2007NephroGene...Cary, N.C.-based NephroGenex, ...--venturebea...